These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19116700)

  • 1. Safety of imipenem/cilastatin in neurocritical care patients.
    Hoffman J; Trimble J; Brophy GM
    Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
    J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients.
    You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F
    J Glob Antimicrob Resist; 2024 Mar; 36():252-259. PubMed ID: 38272210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients" [Journal of Global Antimicrobial Resistance 36 (2024) 252-259].
    You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F
    J Glob Antimicrob Resist; 2024 Mar; 36():494. PubMed ID: 38521551
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolerability of Meropenem and Ertapenem in a Patient with Documented Delayed Hypersensitivity Reaction to Imipenem-Cilastatin: A Literature Review.
    Laajimi R; Mansour K; Chadli Z; Ben Fredj N; Ben Romdhane H; Chaabane A; Aouam K
    Dermatitis; 2024 Apr; ():. PubMed ID: 38634839
    [No Abstract]   [Full Text] [Related]  

  • 7. Come hell or high water: climate change through the lens of neurocritical care.
    Fischer D
    Intensive Care Med; 2023 Dec; 49(12):1526-1528. PubMed ID: 37982823
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction: Relationship of imipenem therapeutic drug monitoring to clinical outcomes in critically ill patients: a retrospective cohort study.
    Wu Y; Lu Z; Liang P; Zhu H; Qi H; Zhang H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5329. PubMed ID: 38334826
    [No Abstract]   [Full Text] [Related]  

  • 9. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.
    Miller AD; Ball AM; Bookstaver PB; Dornblaser EK; Bennett CL
    Pharmacotherapy; 2011 Apr; 31(4):408-23. PubMed ID: 21449629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
    J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seizures as adverse events of antibiotic drugs: A systematic review.
    Sutter R; Rüegg S; Tschudin-Sutter S
    Neurology; 2015 Oct; 85(15):1332-41. PubMed ID: 26400582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses.
    Martin-Canal G; Saavedra A; Asensi JM; Suarez-Zarracina T; Rodriguez-Guardado A; Bustillo E; Fierer J; Carton JA; Collazos J; Asensi V
    Int J Antimicrob Agents; 2010 Mar; 35(3):301-4. PubMed ID: 20045289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.
    Calandra G; Lydick E; Carrigan J; Weiss L; Guess H
    Am J Med; 1988 May; 84(5):911-8. PubMed ID: 3284342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem cilastatin sodium-associated thrombocytopenia in an older patient: A case report and literature review.
    Qiao W; Chang C; Wang Q; Cao X; Zhang X
    Int J Clin Pharmacol Ther; 2022 Aug; 60(8):358-363. PubMed ID: 35652550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative review of imipenem/cilastatin versus meropenem.
    Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
    Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual Drug Fever Caused by Imipenem/Cilastatin and a Review of Literature.
    Yang J; Wang Q; Wang S; Zhang Y; Wang Z
    Heart Surg Forum; 2019 Mar; 22(2):E119-E123. PubMed ID: 31013221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.